---
schema_version: "secwatch.filing_event.v1"
accession: "0001764013-22-000033"
form_type: "8-K"
ticker: "IMVT"
cik: "0001764013"
company_name: "Immunovant, Inc."
filed_at: "2022-03-30T23:59:59+00:00"
generated_at: "2026-06-26T13:48:51.188389+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "low"
source: SEC EDGAR
---

# Immunovant R&D Day presentation filed; details not fully available in text

## Summary
- Immunovant hosted a virtual R&D Day on March 30, 2022; presentation filed as Exhibit 99.1.
- The filed exhibit contains only the title slide; no specific data or updates are extractable from the provided text.
- Investors should refer to the complete presentation for pipeline and clinical trial updates.

## SEC filing metadata
- accession: 0001764013-22-000033
- form_type: 8-K
- ticker: IMVT
- cik: 0001764013
- company_name: Immunovant, Inc.
- filed_at: 2022-03-30T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000033/0001764013-22-000033-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1764013/000176401322000033/imvt-20220330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001764013-22-000033
- JSON: https://secwatch.observer/filing/0001764013-22-000033.json
- Plain text: https://secwatch.observer/filing/0001764013-22-000033.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.